Molecular Determinants of Treatment Resistance in Cervical Cancer: A Systematic Review and Integrative Bioinformatic Analysis of Publicly Available Datasets
Systematic review and bioinformatic analysis reveals treatment resistance signatures in cervical cancer, highlighting lumican as a connected network hub.
Key Points
To identify reproducible transcriptional signatures and candidate molecular drivers associated with therapeutic resistance during cervical cancer progression.
Integrated a systematic review with bioinformatic analyses of publicly available transcriptomic datasets from cervical cancer models exposed to chemotherapy and epigenetic modulators.
Evaluated candidate gene expression profiles across clinical datasets spanning normal cervix, cervical intraepithelial neoplasia, and invasive cervical cancer.
Performed functional enrichment, protein-protein interaction network construction, and survival analyses on consensus candidate genes.
Identified 38 concordantly altered genes across treatment conditions that exhibited progressive dysregulation throughout neoplastic progression to invasive disease.
Functional enrichment demonstrated significant overrepresentation of extracellular matrix organization, metabolic regulation, and p53-associated signaling pathways.
Network analysis prioritized lumican (LUM) as a highly connected hub gene, though no statistically significant association with overall survival was detected.